Drug intelligence / Profile preview

TBD-TNFa

Development stage: Preclinical
Lead developer: OroGen BioSciences
Modality: Small Molecules
Administration: Oral

Overview

TBD-TNFa is a preclinical-stage small molecule inhibitor of tumor necrosis factor-alpha (TNF-alpha) being developed by Orogen Therapeutics (also known as OroGen BioSciences). The drug is designed as an oral alternative to biologic TNF inhibitors for the treatment of autoimmune and inflammatory disorders, with a primary focus on rheumatoid arthritis (RA). By targeting and neutralizing TNF-alpha, TBD-TNFa aims to suppress the chronic inflammatory cascade that drives joint destruction and systemic symptoms in RA patients.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on TBD-TNFa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBD-TNFa.

Explore the full profile